Ionis Pharmaceuticals announced highly positive results from two pivotal Phase III trials assessing olezarsen, an antisense oligonucleotide targeting apolipoprotein-CIII. The CORE and CORE2 trials demonstrated up to a 72% reduction in fasting triglycerides and an 85% decrease in acute pancreatitis events in severe hypertriglyceridemia patients, with favorable safety. Ionis plans to file a supplemental New Drug Application (sNDA) by year-end for this indication, aiming for a 2026 launch. CEO Brett P. Monia emphasized the drug's potential to fulfill significant unmet needs and become a blockbuster. Olezarsen is already FDA-approved for familial chylomicronemia syndrome under the brand Tryngolza®.